Background Takotsubo cardiomyopathy (TC) is an established differential diagnosis of myocardial infarction with non-obstructive coronaries with significant interest but limited data on prognostication. We reviewed the characteristics and in-hospital outcomes and developed a novel risk score for TC. Methods Using the National Inpatient Sample data from 2016 to 2020, we identified adult patients (≥18 years) with acute coronary syndrome (ACS) and TC. We divided the cohort into ACS with and without TC and retrieved baseline data. Multivariable regression analysis was conducted to identify factors associated with TC diagnosis and adverse outcomes, leading to the development of a risk-scoring system. Results Among 7 219 004 adult ACS admissions, 78 214 (1.0%) were diagnosed with TC, with a mean age of 68.2 years, 64 526 (82.5%) being female and 5475 (7.0%, compared with 8.4% for other ACS) in-hospital mortality events. Factors significantly associated with TC were female sex (OR 6.78 (95% CI 6.47 to 7.09), p<0.001) and chronic heart failure (OR 1.60 (95% CI 1.54 to 1.66), p70 years, non-white race, hypertension, hyperlipidemia, history of coronary artery bypass grafting, history of percutaneous coronary intervention, cardiac arrhythmias, renal failure, cardiogenic shock and vasopressor use. The area under curves for in-hospital mortality was 0.716 in the derivation and 0.725 in the validation cohorts. Conclusions TC remains a high-risk diagnosis in a minority of ACS cases, with mortality rates similar to other ACS causes. Our novel risk score offers a valuable tool for risk stratification in patients with TC, but external validation is needed to confirm its utility.

The association of traditional cardiovascular disease (CVD) risk factors with outcomes of Takotsubo syndrome (TTS) is not well-defined. This study examined how modifiable CVD risk factors affect composite cardiovascular outcomes in TTS hospitalizations. TTS admissions were identified using ICD-10 codes and compared for demographics and comorbidities using the 2019 National Inpatient Sample. A multivariable regression examined the association of traditional CVD risk variables with adverse composite cardiovascular outcomes in TTS, controlling for confounders including sociodemographic or hospital-level characteristics and other relevant comorbidities. A total of 16,055 (38.1%) of the 41,855 adult TTS admissions had composite cardiovascular outcomes (TACCO). The TACCO cohort was 81.5% white, 77.3% female, and 72 years old. This group had higher rates of diabetes and peripheral vascular disease (PVD). The results showed that a higher prevalence of diabetes with chronic complications (OR = 1.18) and complicated hypertension (HTN) (OR = 1.1) predicted TACCO, whereas tobacco use disorder (OR = 0.84), hyperlipidemia (OR = 0.76), and uncomplicated HTN (OR = 0.65) (p < 0.001) showed a paradoxical effect with TACCO. TACCO had fewer routine discharges (35.3% vs. 63.4%), longer stays (6 vs. 3 days), and higher median hospital costs (78,309 USD vs. 44,966 USD). This population-based study found that complicated HTN and DM with chronic complications are strongly associated with adverse cardiovascular outcomes in TTS hospitalizations. But still, some risk factors, such as hyperlipidemia and uncomplicated HTN, have counterintuitive effects that require further evaluation. To prevent cardiac events in TTS patients, traditional CVD risk factors must be addressed.

Patients diagnosed with chronic hepatitis are at risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD), liver fibrosis, and hepatocellular carcinoma. We focus on the role of reproductive hormones such as estrogen, progesterone, and androgens on the liver. While estrogen acts as a hepato-protective hormone, androgens display sexual dimorphism. There is evidence linking androgen receptor activity to enhanced hepatitis B viral replication in the liver and its carcinogenic potential. With a growing population opting for gender affirming hormonal treatment (GAHT), the transmasculine population receiving testosterone supplementation needs to undergo monitoring of their liver enzymes. Mild elevation in hepatic enzymes in the transmasculine population may be noted; however, it is not associated with liver dysfunction. Hormone replacement therapy (HRT) in menopausal women has been shown to improve liver function and improve mortality by reducing the risk of hepatocellular carcinoma. It is important to understand the risk of peripartum complications in females with chronic hepatitis B infection. Serial monitoring of hepatitis B surface antigen (HBsAg), HBeAg, antibody to HBeAg (anti-HBe), HBV DNA, and the presence of other viral infections is recommended in pregnant patients with a known history of hepatitis B. By integrating clinical evidence and pathophysiological mechanisms, this chapter aims to highlight the need for gender-specific approaches to diagnosis, monitoring, and management of chronic hepatitis to improve reproductive and endocrine health in affected women.